Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
The Ras Gene02:38

The Ras Gene

6.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

4.3K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Catamenial Pneumothorax as an Underrecognized Manifestation of Thoracic Endometriosis: A 25-Year Single-Center Experience.

Journal of clinical medicine·2026
Same author

Visualization of the thoracic sympathetic chain in MLS embalmed body donors: a feasibility study and surgical perspective.

Journal of thoracic disease·2026
Same author

msBayesImpute as a versatile framework for addressing missing values in biomedical mass spectrometry proteomics data.

Communications chemistry·2026
Same author

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.

Clinical lung cancer·2026
Same author

The evolving role of cytokines for CAR-T cell manufacturing and beyond.

Nature biomedical engineering·2026
Same author

Spatial proteomics profiling reveals oncogene-specific immune niches and prognostic markers in NSCLC.

American journal of respiratory and critical care medicine·2026

Related Experiment Video

Updated: Sep 29, 2025

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.6K

An In Vivo Inflammatory Loop Potentiates KRAS Blockade.

Kristina A M Arendt1,2, Giannoula Ntaliarda3, Vasileios Armenis3

  • 1Comprehensive Pneumology Center (CPC), Institute of Lung Health and Immunity (LHI), Helmholtz Zentrum München, 81377 Munich, Germany.

Biomedicines
|March 25, 2022
PubMed
Summary

KRAS inhibitors fail in clinical trials because KRAS-mutant tumors hijack myeloid cells via CCL2/IL-1β signaling. Blocking IL-1β may be a viable therapy for KRAS-mutant cancers.

Keywords:
IL-1βIL1R1KRASKRAS mutationKRASG12Cdeltarasininflammationlung cancer

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K
Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells
09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.5K

Related Experiment Videos

Last Updated: Sep 29, 2025

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.6K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K
Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells
09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • KRAS inhibitors show limited efficacy in vitro and clinical trials.
  • The underlying mechanisms for KRAS inhibitor failure are not fully understood.

Purpose of the Study:

  • To investigate why KRAS inhibitors underperform in vitro and fail clinical trials.
  • To elucidate the role of myeloid cells and signaling pathways in KRAS-mutant tumor resistance.

Main Methods:

  • Treatment of human and murine tumor cells with KRAS inhibitors (deltarasin, cysmethynil, AA12).
  • Gene silencing and overexpression of mutant KRAS.
  • In vivo studies using gene-deficient mice (Ccr2, Il1b) and bone marrow transplantation.
  • Transcriptome analysis of human cancers.

Main Results:

  • KRAS-mutant tumors exclusively respond to KRAS blockade in vivo.
  • Tumor cells co-opt myeloid cells via CCL2/IL-1β signaling for sustained tumorigenicity.
  • KRAS-mutant tumors showed resistance in Ccr2/Il1b-deficient mice but sensitivity in wild-type settings.
  • A KRAS-dependent pro-inflammatory transcriptome correlated with high KRAS mutation prevalence and poor survival.

Conclusions:

  • In vitro systems are suboptimal for anti-KRAS drug screening due to KRAS inhibitors suppressing IL1R1 expression and myeloid IL-1β effects in vivo.
  • IL-1β blockade could be a potential therapeutic strategy for KRAS-mutant cancers.